Comparative Pharmacology
Head-to-head clinical analysis: GLUCOTROL versus LOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOTROL versus LOGEN.
GLUCOTROL vs LOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor 1 (SUR1) on ATP-sensitive potassium channels, causing depolarization and calcium influx. Also may increase peripheral insulin sensitivity.
LOGEN (lofepramine) is a tricyclic antidepressant that primarily inhibits the reuptake of norepinephrine and, to a lesser extent, serotonin at the presynaptic nerve terminal, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminic, and alpha1-adrenergic blocking properties.
Initial dose 5 mg orally once daily, increased by 2.5-5 mg increments weekly based on glycemic response; maximum 20 mg daily as single or divided doses (for doses >15 mg, administer in divided doses).
1-2 tablets (5-10 mg loperamide) orally after first loose stool, then 1 tablet (5 mg) after each subsequent loose stool; maximum 8 tablets (40 mg) per day for acute diarrhea; 4-8 tablets (20-40 mg) daily in divided doses for chronic diarrhea.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (mean 3.4 hours) in normal subjects; extended up to 8-12 hours in elderly or hepatic impairment due to reduced clearance.
Terminal half-life is 2-4 hours in adults with normal renal function; extends to 8-12 hours in renal impairment. Clinical context: requires frequent dosing or renal dose adjustment.
Primarily renal: ~80% as metabolites (mainly 4-trans-hydroxyglipizide and 3-cis-hydroxyglipizide) and ~10% unchanged; fecal: ~10%.
Renal excretion dominates: 70-80% of the dose is eliminated unchanged in urine; biliary/fecal excretion accounts for 10-15%. Minimal hepatic metabolism.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic